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Abstract
Background and Aims: Erythropoietin (EPO) is a glycoprotein hormone which is required to regulate the production
of red blood cells. Deficiency of EPO is known to cause anemia in chronically infected renal patients and they require
regular blood transfusion. Availability of recombinant EPO has eliminated the need for blood transfusion and now it is
extensively used for the treatment of anemia. Glycosylation of erythropoietin is essential for its secretion, stability,
protein conformation and biological activity. However, maintenance of human like glycosylation pattern during
manufacturing of EPO is a major challenge in biotechnology. Currently, Chinese hamster ovary (CHO) cell line is used
for the commercial production of erythropoietin but this cell line does not maintain glycosylation resembling human
system. With the trend to eliminate non-human constituent from biopharmaceutical products, as a preliminary
approach, we have investigated the potential of human hepatoma cell line (Huh-7) to produce recombinant EPO.
Materials and methods: Initially, the secretory signal and Kozak sequences was added before the EPO mature
protein sequence using overlap extension PCR technique. PCR-amplified cDNA fragments of EPO was inserted into
mammalian expression vector under the control of the cytomegalovirus (CMV) promoter and transiently expressed
in CHO and Huh-7 cell lines. After RT-PCR analysis, ELISA and Western blotting was performed to verify the
immunochemical properties of secreted EPO.
Results: Addition of secretory signal and Kozak sequence facilitated the extra-cellular secretion and enhanced the
expression of EPO protein. Significant expression (P < 0.05) of EPO was observed in the medium from Huh-7 cell line.
Conclusion: Huh-7 cell line has a great potential to produce glycosylated EPO, suggesting the use of this cell line
to produce glycoproteins of the therapeutic importance resembling to the natural human system.
Keywords: EPO, erythropoietin; CHO, Chinese hamster ovary cell line; Huh-7, Human hepatoma cell line; PCR,
polymerase chain reaction
Introduction
EPO is an essential growth factor required for the prolif-
eration and differentiation of the stem cells that produce
red blood cells [1]. Structurally, EPO is a glycoprotein
contains approximately 40% carbohydrate [2]. These car-
bohydrate structures are very essential for many biologi-
cal properties like pharmacokinetics, secretion, stability,
receptor recognition and antigenicity, protein conforma-
tion and biological activity [3].
Kidney is the main production unit of EPO in normal
person [4]. Any damage to kidney tissues abolishes the
EPO secretion from kidney thus causing anemia in renal
patients. Recombinant DNA technology has enabled
manufacture of the recombinant human EPO (rHuEPO)
to use as a drug. The initial findings with the use of
rHuEPO for the treatment of anemia were so inspiring
that it was licensed to use as therapy within three years
of its availability [5]. Now the drug is amongst the top
selling pharmaceutical product worldwide and consid-
ered applicable for a variety of disorders such as anemia
associated with renal failure, hepatitis C infection, cancer,
human immunodeficiency virus infections, and cardio-
vascular disease [6].
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any medium, provided the original work is properly cited.The glycosylation pattern of protein is affected by sev-
eral parameters including the protein structure [7], host
system used to produce glycoprotein [8] and the culture
conditions [9]. Among all these parameters, host system
greatly affects the glycosylation pattern, thus selection of
appropriate host system is very crucial to produce the
therapeutic glycoprotein. Among the prokaryotic and
eukaryotic expression systems only mammalian cell lines
have the capacity to carry out proper glycosylation.
Currently, the mammalian system used to produce
the rHuEPO is CHO cell line [10] associated with some
disadvantages e.g. it is not able to control the human like
glycosylation. EPO produced from CHO cells contains
N-glycolylneuraminic acid [11], but humans lack the path-
w a yf o rt h es y n t h e s i so fN-glycolylneuraminic acid [12],
thus recombinant EPO that contain N-glycolylneuraminic
acid are subjected to clearance by anti-N-glycolylneurami-
nic acid antibodies present in human serum [13]. Thera-
peutic use of such glycoproteins may cause undesirable
responses that can affect the efficacy of the treatment. So
the use of human cell line for therapeutic glycoproteins
production is unavoidable. Human-cell based expression
system can provide some unique characteristics to bio-
pharmaceutics including lower immunogenicity, greater
biological activity and increased half life.
With the trend to introduce the human-cell-based
expression system to synthesize the biopharmaceutical
products, several human cell lines have been proposed e.g.
Human embryonic kidney (HEK293) and human fibro-
sarcoma (HT-1080) cell line [14]. In the present study, we
have used Huh-7 cell line for the first time for expression
study of EPO gene in comparison to CHO cell line. Pre-
viously this cell line was used for the expression study of
insulin [15,16]. Huh-7 cell line is derived from epithelial
cells of human liver. We hypothesized that EPO produced
from human liver cell line would be properly folded and
glycosylated, as EPO is mainly produced by liver cells dur-
ing the fetal stage [17].
Materials and methods
Construction of vectors for erythropoietin gene
expression
EPO-cDNA construct pcDNA3.1-EPO containing only
mature EPO protein sequence (495 bp) was provided by
CEMB (Centre of Excellence in Molecular Biology, Uni-
versity of the Punjab, Lahore). For the construction of
EPO secretory plasmid, we used this plasmid as a starting
material. PCR-based addition of secretory signal was per-
formed for extra-cellular protein secretion using the six
over lapping primers (Table 1) at 5’ end of EPO-cDNA
construct. Final PCR product was a fragment of 588 bp,
having 495 bp of mature EPO protein sequence, 81 bp of
secretory signal peptide and 12 bp of EcoR1 and BamH1
restriction sites at 5’ and 3’ end respectively (Figure 1).
PCR-product was digested with EcoR1 and BamH1 (Fer-
mentas, USA) and used for ligation into plasmid
pcDNA3.1/zeo the resulting plasmid was named as
pcDNA3.1-SS-EPO (Figure 2A).
In another approach six nucleotides of Kozak sequence
(GCCACC), was also added before the start codon of
EPO-cDNA construct by using the primer K as forward
and primer R as reverse primers (Table 1). The size of this
fragment was 594 bp including the Xho1a n dBamH1
restriction sites at 5’ and 3’ end respectively. PCR-product
was digested with Xho1 and BamH1 and used for ligation
into plasmid pcDNA3.1/zeo the resulting plasmid was
named as pcDNA3.1-K-SS-EPO (Figure 2A). Following
transformation and subsequent plasmid purification, of
randomly selected clones, restriction digestion and
sequencing analysis was performed using Big Dye chain
termination reaction on an ABI 3100 DNA sequencer
(Applied BioSystem) to verify the cloning of EPO-cDNA
constructs in expression vector.
Cell culture
Huh-7 cell line was maintained in 75 cm
2 culture flasks
(Iwaki, Japan) containing DMEM (Sigma Aldrich, USA)
supplemented with 100 μg/ml penicillin/streptomycin, and
10% FBS as complete culture media (CCM) (Sigma
Aldrich, USA), at 37°C with 5% CO2. The CCM was
renewed every third day and were passaged every 4-5 days.
Viable cells were counted using 0.5% trypan blue (Sigma
Aldrich, USA). Similarly CHO cell line was maintained in
DMEM Ham’s F12 (Sigma Aldrich, USA) and maintained
as described for Huh-7 cells.
Transient transfection
Approximately 3.5 × 10
5 CHO cells were seeded into 60
mm plates and cultured in CCM until 60-80% confluent
prior to transfection. 8 μg of pcDNA3.1-EPO, pcDNA3.1-
SS-EPO and pcDNA3.1-K-SS-EPO was transiently
Table 1 Primer sequences
Signal sequence and Kozak addition
Primer 1 CTCCCAGTCCTGGGCGCCCCACCACGCCTC
Primer 2 TCGCTCCCTCTGGGCCTCCCAGTCCTGGGC
Primer 3 CTCCTGTCCCTGCTGTCGCTCCCTCTGGGC
Primer 4 GCCTGGCTGTGGCTTCTCCTGTCCCTGCTG
Primer 5 GTGCACGAATGTCCTGCCTGGCTGTGGCTT
Primer 6 GAATTCATGGGGGTGCACGAATGTCCTGCC
Primer K CTCGAGGCCACCATGGGGGTGCACGAATGT
Primer R GGATCCTCAGTCCCCTGTCCTGCAGGC
RT-PCR
Forward AGTTAATTTCTATGCCTGGAAGAGG
Reverse GGAAAGTGTCAGCAGTGATTGTT
GAPDH-F ACCACAGTCCATGCCATCAC
GAPDH-R TCCACCACCCTGTTGCTGTA
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Lipofectamine™ 2000 (Invitrogen) according to the manu-
facturer’s protocol. After 6 hours incubation at 37°C in 5%
CO2, cells were washed with 1x PBS and CCM was added
to the cells. Cells were harvested at 24 hours post-transfec-
tion to analyze the EPO expression at mRNA and protein
level. Similarly the Huh-7 cells were transfected as
described above.
RT-PCR (Reverse transcriptase PCR)
For EPO gene expression analysis, total RNA from Huh-
7 and CHO cells transiently transfected with mock, EPO
expression plasmids was extracted using Purescript RNA
isolation kit (Gentra, USA) according to manufacturer’s
protocol. cDNA was synthesized using 1 μgo ft o t a l
RNA with SuperScript III enzyme (Invitrogen, USA).
EPO gene expression analysis was carried out using RT-
PCR on ABI 2700 PCR machine using gene specific pri-
mers. PCR conditions were as follow: 95°C, 30 sec; 57°C,
30 sec and extension at 72°C for 40 sec for 30 cycles.
GAPDH was used as an internal control.
ELISA (Enzyme Liked Immunosorbent assay)
For intra-cellular expression analysis of EPO, cells were
harvested with ProteoJET mammalian cell lysis reagent
(Fermentas, Canada) and for extra-cellular EPO expression
supernatant was collected after 24 hours of transfection.
Intra and extra-cellular EPO expression analysis was per-
formed through ELISA (DRG, USA) according to manufac-
turer’s protocol. Total 50 μg of intra-cellular protein and
200 μl of media for extra-cellular EPO expression analysis
were subjected to ELISA. Absorbance was read at 450 nm
on ELISA plate reader to determine the concentration of
EPO in samples. The intensity of the yellow color devel-
oped was directly proportional to the concentration of
EPO.
Western Blotting
Mature erythropoietin is secreted into the medium, so
supernatant was collected for comparative extra-cellular
EPO expression analysis from CHO and Huh-7 cells, 24
hours post transfection. Samples and commercially avail-
able recombinant human erythropoietin (as a positive
Figure 1 Construction and PCR confirmation of the expression vector of EPO after the addition of secretory signal by using
overlapping primers. (A) Schematic diagram showing the signal sequence addition using six overlapping primers before the 495 bp of mature
EPO. Sequences of primers are given in Table 1. (B) Agarose gel electrophoresis showing step wise addition of secretory signal. M, 100bp DNA
ladder; Lane 1-6 sequential addition of secretory signal sequence, after every PCR 15-18 bp of the secretory signal is added. The final 588 bp
(including restriction sites) fragment of the EPO fused with 81 bp of signal peptide is achieved.
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SDS-PAGE and electrophoretically transferred to a nitro-
cellulose membrane using manufacturer’sp r o t o c o l( B i o -
Rad, USA). Blots were incubated with specific-monoclonal
antibodies of EPO (Santa Cruz Biotechnology, Inc, USA).
Protein expression was evaluated using chemilumines-
cence detection kit (Sigma Aldrich, USA).
Results and discussion
Construction of secretory plasmid
Recombinant proteins are targeted to the secretory path-
way for post-translational modifications and proper fold-
ing. This is because of the fact that enzymes responsible
for posttranslational modifications, e.g. glycosylation, are
found within the endoplasmic reticulum and Golgi bodies
[18]. Secretion of protein into the media especially of
pharmaceutically importance facilitate the separation of
specific protein from the intra-cellular pool of proteins,
thus the purification and other downstream processing
become easier. Keeping in view the importance of secre-
tory signal we added the EPO’s native secretory signal [19]
at amino terminus of mature EPO protein. Using overlap
extension PCR technique we successfully added 81 nucleo-
tides of secretory signal at 5’ end of mature EPO protein
sequence (Figure 1). Finally, a fragment of 588 bp encod-
ing signal peptide and EPO mature protein was cloned
into pcDNA3.1/zeo (-ve) vector. The cloned fragment was
sequenced to confirm the orientation and sequence of
E P Og e n eb yc o m p a r i n gw i t ht h er e p o r t e dE P Og e n e
sequence. The secretion efficiency of the plasmid was eval-
uated by transfecting the both plasmids without secretory
signal (pcDNA3.1-EPO) and with secretory signal
(pcDNA3.1-SS-EPO) in CHO cell line. Equal numbers of
cells (3.5 × 10
5) were plated and same amount of both
plasmid DNA (8 μg) were used for transfection. Twenty
four hours post-transfection RNA was isolated and quanti-
fied using nanodrop (ND-1000). Total 1 μg of cellular
RNA was reverse transcribed into cDNA and subjected to
RT-PCR analysis. Results of RT-PCR showed that both
plasmids (with and without signal sequence) transcribed
the similar level of EPO mRNA. GAPDH gene was used as
an internal control (Figure 2B). Intra- and extra-cellular
Figure 2 EPO cDNA constructs and their expression analysis in CHO cell line. (A) Schematic diagram showing the three EPO expression
vectors pcDNA3.1-EPO (without secretory signal, having only mature EPO protein sequence of 495 bp), pcDNA3.1-SS-EPO (with secretory signal
fused with mature EPO protein sequence) and pcDNA3.1-K-SS-EPO (having additional six nucleotide of Kozak sequence (GCCACC) before ATG
start codon). CMV promoter region of pcDNA 3.1 vector is also shown. (B) mRNA expression analysis showing equal level of expression of all
three vectors. 1 μg of the total RNA extracted from CHO cells after 24 hours post transfection was subjected to reverse transcriptase PCR. Lane 1,
CHO cells as mock Lane 2, 3 and 4 showing mRNA expression of pcDNA3.1-EPO, pcDNA3.1-SS-EPO and pcDNA3.1-K-SS-EPO respectively. GAPDH
is used as internal control. All experiments were performed in duplicate.
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observed that EPO protein was hardly secreted in the
medium when pcDNA3.1-EPO was transfected, although
it was produced intra-cellularly (Figure 3). In comparison,
medium samples obtained from cells transfected with
pcDNA3.1-SS-EPO gave more absorbance that showed a
significant amount of EPO secreted into the medium (P =
0.006). Interestingly, we also found that addition of secre-
tory signal peptide not only facilitated the secretion of
EPO but a slight increase in intra-cellular protein expres-
sion was also observed. These findings suggest that overall
translation efficiency of EPO gene was also affected after
the addition of secretory signal peptide. As Stenstrom et
al. reported that the presence of initiation codon as well as
context of initiation codon influence the level of gene
expression [20]. Another possible explanation of the find-
ings might be the proper recruitment of the EPO mRNA
to the endoplasmic reticulum after the signal sequence
addition. If the targeting is not fast enough, this may cause
the decrease in protein synthesis and secretion [21].
Effect of Kozak sequence on erythropoietin expression
For the efficient production of recombinant proteins in
mammalian expression system Kozak sequence could be
used as a translation enhancer sequence [22]. After the
confirmation of the functionality of secretory signal, we
aimed to examine whether EPO expression is affected by
adding Kozak sequence or not. For this purpose, we
added the six nucleotides of Kozak sequence (GCCACC)
before the start codon of EPO gene. We observed
increased expression of EPO protein after the addition of
Kozak sequence, as the higher amounts of intra-and
extra-cellular EPO protein was obtained when
pcDNA3.1-K-SS-EPO (P = 0.001) was transfected in
CHO cell line compared to pcDNA3.1-SS-EPO (without
Kozak) (Figure 4). In order to investigate whether the
observed increased in expression level caused by the
inclusion of Kozak sequence into EPO cDNA construct
take place at the stage of transcription or translation, the
levels of EPO mRNA in transfected cell populations were
determined by semi quantitative RT-PCR. Our RT-PCR
results showed that the both plasmids with and without
Kozak transcribed the EPO mRNA with equal efficiency
(Figure 2). As in both plasmids EPO gene construct was
present under the control of same promoter i.e. CMV.
Comparative expression analysis of EPO in CHO and Huh-
7 cell line
Prior to evaluate the potential of Huh-7 cell line to pro-
duce and secrete the EPO protein, we first compared
the translation and secretion efficiency of all three EPO
cDNA constructs in CHO cell line (Figure 3 and 4). We
selected the plasmid pcDNA3.1-K-SS-EPO for compara-
tive expression analysis of EPO gene in CHO and Huh-
7 cell line as this plasmid displayed high levels of EPO
translation and secretion efficiency because it contained
the both translation enhancing elements i.e. secretory
signal sequence and Kozak sequence. So to be able to
Figure 3 Intra and extra-cellular expression of EPO after the addition of secretory signal sequence. Total protein was extracted and
subjected to ELISA. Optical density was measured at 450 nm. (A) Relative extra-cellular EPO expression showing that after the addition of signal
peptide secretion of EPO into the medium is dramatically increased. (B) Comparison of intra-cellular EPO expression with (pcDNA3.1-SS-EPO) and
without signal peptide (pcDNA3.1-EPO) expression vectors. Intra-cellular expression of protein is also slightly increased after the addition of signal
peptide.
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line, equal amount of plasmid was transiently trans-
fected in both cell lines. EPO gene expression was ana-
lyzed at both mRNA and protein level. Our RT-PCR
results showed approximately same amount of EPO
mRNA transcribed from both cell lines (Figure 5A).
ELISA analysis showed significant (P < 0.05) increase in
EPO secretion in medium collected from Huh-7 cell
Figure 4 Intra and extra-cellular expression analysis of EPO with and without Kozak sequence addition, through ELISA. Optical density
was measured at 450 nm. Both intra and extra-cellular EPO expression increased after the addition of Kozak sequence. (A) Comparison of extra-
cellular EPO expression with Kozak (pcDNA3.1-K-SS-EPO) and without Kozak sequence (pcDNA3.1-SS-EPO) expression vectors. (B) Comparison of
intra-cellular EPO expression after the addition of Kozak.
Figure 5 Comparative expression analysis of EPO in CHO and Huh-7 cell line. (A) mRNA expression analysis showing equal level of
expression of pcDNA3.1-K-SS-EPO vector in CHO and Huh-7 cell line. 1 μg of the total RNA extracted from CHO and Huh-7 cells after 24 hours
post transfection was subjected to reverse transcriptase PCR. Lane 1, mock Huh-7 cells; Lane 2, EPO gene expression in Huh-7; Lane 3, CHO cells
as mock; Lane 4, EPO gene expressing in CHO cell line. GAPDH is used as an internal control. (B) Comparative expression analysis of extra-
cellular level of EPO protein through ELISA in CHO and Huh-7 cell line. 8 μg of the pcDNA3.1-K-SS-EPO vector was transfected in Huh-7 and
CHO cell line, 24 hours post transfection media was collected and 200 μl of media was loaded on EPO antigen coated ELISA plates. Graph is
showing that Huh-7 cells secreted the increased amount of EPO and difference in expression level is significant (P < 0.05). (C) Extra-cellular
protein expression levels were determined by Western blot analysis in CHO and Huh-7 cell lines using EPO specific antibodies. Lane1,
Commercially available purified EPO protein as standard; Lane 2, Huh-7 cells as mock; Lane 3, EPO expressed from Huh-7cell line; Lane 4, CHO
cells as mock; Lane 5, EPO expressed from CHO cells.
Kausar et al. Journal of Translational Medicine 2011, 9:186
http://www.translational-medicine.com/content/9/1/186
Page 6 of 8line compared to CHO cell line (Figure 5B). One possi-
ble explanation for this increased expression of EPO
from Huh-7 cell line is might be the effect of Kozak
sequence. It is reported that effect of Kozak on protein
expression varies among host systems [23]. Although,
CHO cell line also showed increase expression level
after the addition of Kozak sequence (Figure 4) but
higher expression in Huh-7 cells suggest that Kozak
consensus sequence might be more compatible with the
human cell line. Further experiments, involving the
other human and non-human but mammalian cell lines
can be used to test this possibility. ELISA results were
further confirmed by western blot analysis. Results of
western blot verified the immunochemical properties of
secreted EPO. EPO attains its size of 34 KDa after
proper glycosylation during posttranslational modifica-
tion whereas, unglycosylated form has lower molecular
weight (18.4 KDa), indicated by smaller size protein on
SDS-PAGE. In accord with this evidence, we observed a
similar sized EPO protein (34 KDa) on Western blot
when run side by side with commercially available gly-
cosylated EPO as positive control suggesting that CHO
and Huh-7 cell lines produced glycosylated form of EPO
(Figure 5C) based upon their size similarity.
Our results showed that Huh-7 cells have the potential
to secrete the comparable level of EPO to the CHO cell
line which is already being used for commercial produc-
tion of erythropoietin. Although, CHO cell line has several
advantages including high growth rate and high productiv-
ity, but human cell-based expression is expected to pro-
duce EPO with post-translational modifications similar to
their natural counterpart as some sugar tarnsfering
enzymes are not present in CHO cell line e.g. a2-6 sialyl-
transferase and a1-3/4 fucosyltransferase [24].
In many studies people have used Huh-7 cell line as
model system for expression studies of human proteins
[25-28]. In the present study, Huh-7 cell line has shown
the potential to produce the glycosylated EPO protein as
an initial finding. However, to produce EPO at commercial
level using Huh-7 cell line further characterization should
be undertaken to determine the exact extent of sialylation,
as it is reported that increased sialylation of EPO has been
shown to increase its circulatory half-life. And this could
be done through high pH anion exchange chromatography
and isoelectric focusing.
Further studies to evaluate the bioactivity, up scalability
and compatibility of Huh-7 cells with bioreactor are also
needed. These findings will not only assist the biophar-
maceutical industry by providing a human-cell-based
expression system to produce recombinant glycosylated
protein but, is also a preliminary step to make use of liver
cells to deliver the EPO gene in chronically infected renal
patients to cure anemia.
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